Drug Type Small molecule drug |
Synonyms Atiprimod, Atiprimod dihydrochloride (USAN), Azaspirane + [5] |
Target |
Mechanism IL-6 modulators(Interleukin-6 modulators), STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H46Cl2N2 |
InChIKeyMOUZYBYTICOTFQ-UHFFFAOYSA-N |
CAS Registry130065-61-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03003 | Atiprimod dihydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Carcinoid Tumor | Phase 2 | US | 10 Aug 2022 | |
Neuroendocrine Carcinoma | Phase 2 | US | 01 Oct 2006 | |
Advanced cancer | Phase 2 | US | 01 Mar 2005 | |
Refractory Multiple Myeloma | Phase 2 | US | 01 May 2004 | |
Relapse multiple myeloma | Phase 2 | US | 01 May 2004 | |
Multiple Myeloma | Phase 2 | - | - | |
Multiple Myeloma | Phase 2 | - | - | |
Multiple Myeloma | Phase 2 | - | - | |
Osteoarthritis | Phase 2 | - | - | |
Osteoarthritis | Phase 2 | - | - |
Phase 2 | 23 | tqxsxsmany(fproyprugc) = lfxviuaags tbndrpmsyt (dwukfswewc ) | - | 20 May 2008 |